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ABSTRACT
Hepatocellular carcinoma (HCC) is characterized by limited response to current 
drug therapies. Here, we report that SC66, a novel AKT inhibitor, reduced cell viability 
in a dose- and time-dependent manner, inhibited colony formation and induced 
apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-
AKT levels. This was associated with alterations in cytoskeleton organization, a 
reduction in expression levels of E-cadherin, β-catenin and phospho-FAK, together 
with up-regulation of Snail protein levels. All these alterations were coupled with 
anoikis cell death induction. In addition, SC66 induced the production of reactive 
oxygen species (ROS) and DNA damage. Pre-treatment with the ROS scavenger 
N-Acetyl-cysteine (NAC) prevented SC66-induced cell growth inhibition and anoikis. 
SC66 significantly potentiated the effects of both conventional chemotherapeutic and 
targeted agents, doxorubicin and everolimus, respectively. In vivo, SC66 inhibited 
tumor growth of Hep3B cells in xenograft models, with a similar mechanism observed 
in the in vitro model. Taken together, these data indicate that the AKT inhibitor SC66 
had antitumor effects on HCC cells. This was mediated by ROS production, induction 
of anoikis-mediated cell death and inhibition of the AKT cell survival pathway. Our 
results provide a rational basis for the use of SC66 in HCC treatment.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer worldwide, characterized by an increasing 
incidence and a poor prognosis [1–5]. HCC is largely 
asymptomatic until it is in the advanced state when the 
treatments available are often unsuccessful. The standard 
treatments are surgical resection and liver transplantation, 
but they are indicated only in specific conditions, however 
both are rarely successful. Other treatments, such as 
chemoablation, focused ultrasound and radiation also 
rarely lead to complete recovery [5]. Standard cancer 
drugs such as doxorubicin, cisplatin, and 5-fluorouracil 
have very limited efficacy [5].
Today, sorafenib, a Raf kinase inhibitor approved 
by the FDA and EMEA for the treatment of patients with 
advanced and unresectable HCC, is the only systemic 
therapy which improves survival in HCC patients [6]. 
Although sorafenib improves prognosis in advanced HCC, 
response to sorafenib remains low and the median overall 
survival is only extended by a few months [6–10].
The development of new specific therapies is 
necessary. However, recent knowledge of the oncogenic 
processes and signaling pathways that regulate tumor cell 
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proliferation, differentiation, angiogenesis, invasion and 
metastasis has led to the identification of several potential 
molecular targets and to the development of specific 
targeted molecular therapies.
The PI3K/AKT/mTOR signaling pathway is involved 
in various cellular processes such as cell proliferation, 
migration, survival and angiogenesis. In PI3K/AKT/
mTOR signaling, activated receptors trigger the activation 
of PI3K and the conversion (by its catalytic domain), of 
phosphatidylinositol (3,4)-bisphosphate (PIP2) lipid to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). AKT 
binds to PIP3 at the plasma membrane, allowing PDK1 
to phosphorylate AKT to T308, leading to partial AKT 
activation [11, 12]. Phosphorylation of AKT at S473, either 
by mTOR [13] or by DNA-PK [14], stimulates full AKT 
activity. Full activation of AKT leads to additional substrate-
specific phosphorylation events in both the cytoplasm and 
nucleus [15]. Fully-active AKT mediates numerous cellular 
functions including angiogenesis, metabolism, growth, 
proliferation, survival, protein synthesis, transcription and 
apoptosis.
Phosphorylation of AKT at S473 has been detected 
in up to 71% of HCC samples and associated with the 
invasion, metastasis, and vascularization of HCC [16].
Activated AKT positively modulates mammalian 
target of rapamycin (mTOR) function. mTOR phos-
phorylates components of the protein synthesis machinery, 
such as the serine-threonine kinase p70S6 (40S ribosomal 
protein kinase) and the translation repressor eukaryotic 
initiation factor 4E-binding protein-1 (4E-BP1), both 
regulating the translation of important factors involved in 
cell proliferation (such as c-myc, cyclic D1 and pRb) and 
angiogenesis (such as HIF1-α). Aberrant mTOR signaling 
has also been detected in up to 48% of HCC cases, and a 
correlation between poor outcome and mTOR signaling 
activation has been shown [17, 18]. These results make 
the AKT/mTOR signaling a promising target for new 
therapies in HCC [19–22].
However, the clinical relevance of the AKT/mTOR 
pathway as a key target in HCC and its therapeutic 
potential as a target for therapy remain to be elucidated. 
Recently, the novel AKT inhibitor SC66 has been 
demonstrated to promote cell death in cervical cancer 
through disruption of mTOR signaling [23]. SC66 is 
an allosteric inhibitor which displays a dual-inhibitory 
function toward AKT activity: i) deactivation by facilitated 
ubiquitination, and ii) inhibition by directly interfering 
with the pleckstrin homology (PH) domain binding to 
PIP3 [24].
In this study, we analyzed the antitumor activity of 
SC66 in HCC cells in vitro and in vivo. We demonstrated 
that treatment with SC66 induced cell growth inhibition, 
inhibition of colony formation and anoikis through ROS 
production. SC66 significantly inhibited cell viability in 
combination with doxorubicin and everolimus. SC66 was 
also effective in in vivo xenograft-bearing mice where 
it displays significant tumor growth reduction. These 
findings suggest that SC66 might represent a promising 
new therapeutic drug for HCC treatment.
RESULTS
SC66 inhibits cell viability and colony forming 
capacity of HCC cells
To investigate the effects of SC66 on HCC cell 
viability, HepG2, Huh7, Hep3B, PLC/PRF/5 and 
HA22T/VGH cell lines were incubated with increasing 
concentrations of SC66 and cell viability was analyzed 
after 24, 48 and 72 hours. Our results demonstrated that 
treatment with SC66 reduced cell viability in a dose- and 
time-dependent manner (Figure 1A). Each cell line had a 
different sensitivity to the drug, as evidenced by the IC
50
 
values shown in Table 1. HepG2, HA22T/VGH and PLC/
PRF/5 cells had similar IC
50
 values of approximately 0.85 
and 0.75 μg/ml at 48 and 72 hours, respectively. The most 
resistant cell line was Huh7, which showed an IC
50
 of 
3.1 and 2.8 μg/ml at 48 and 72 hours respectively, while 
the Hep3B cell line was found to be the most sensitive, 
with an IC
50
 of 0.75 and 0.5 μg/ml at 48 and 72 hours, 
respectively. For example, at 24 hours the highest dose 
tested (4 μg/ml) inhibited Huh7 cell viability by almost 
30% and Hep3B cell viability by almost 90% (Figure 1A), 
therefore we selected these two cell lines for all further 
experiments.
Next, we performed a colony forming assay (Figure 
1B), which mimics the clonogenic survival of tumor cells 
in a solid tumor environment. SC66 displayed a strong 
inhibition of colony forming capacity, and this type of 
assay also confirmed that Hep3B cells have a higher 
sensitivity to the drug than Huh7 cells (Figure 1B).
SC66 induces apoptosis
To determine whether the decrease in cell viability 
was related to apoptosis induction, TUNEL assays were 
performed in Hep3B and Huh7 cells treated with 1, 2 
and 4 μg/ml of SC66 for 24 hours. As shown in Figure 
2A, in Hep3B cells the number of TUNEL-positive cells 
increased with increasing concentrations of SC66, whereas 
in Huh7 cells very few light brown-colored cells were 
observed only after treatment with 4 μg/ml SC66.
Apoptosis was also quantified by flow cytometry 
analysis of DNA stained with propidium iodide and by 
determining the percentage of events accumulating in 
the subG1 position (Figure 2B). Treatment with 2 μg/
ml SC66 increased apoptotic Hep3B cells to 17.5% ± 
0.3 compared to control, whereas the percentage of 
apoptotic cells was only 4.5% ± 0.8 in the more resistant 
Huh7 cells. Consistent with the apoptosis detected 
in Hep3B cells, the kinetics of caspase-3/7 activity 
measured by fluorometric caspase-3/7 assay showed 
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Figure 1: SC66 is cytotoxic to HCC cell lines. (A) Cell viability in each HCC cell line was assessed by MTS assays. Cells were treated 
with increasing concentrations of SC66 for 24, 48 and 72 hours. Data are expressed as the percentage of control cells and are the means ± SD of 
three separate experiments, each of which was performed in triplicate. (B) Representative images of clonogenic assay after treatment with SC66. 
Hep3B and Huh7 cells were plated overnight and exposed to SC66 at the indicated concentrations for 48 hours. After treatment each well was 
washed and the experiment continued for 14 days in the absence of drugs. Surviving colonies were stained (left panel) and counted (right panel). 
Data are expressed as a numbers of colonies and are the means ± SD of two separate experiments, each of which was performed in duplicate.  
*p < 0.05, **p < 0.001 versus control vehicle alone.
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early activation of caspase-3/7 starting as little as 1 hour 
after treatment (Figure 2C). Caspase activity after 1, 3 
and 6 hours of SC66 exposure was significantly higher 
in Hep3B cells treated with SC66 2 and 4 μg/ml than in 
Hep3B cells treated with vehicle alone (p < 0.001). In 
Huh7 cells, we observed a 1.3 fold increase in caspase 
activity only at 24 hours and only with the highest drug 
dose (data not shown).
Finally, Western blot analysis of protein extracted 
from Hep3B cells after treatment for 24 hours with 2 
and 4 μg/ml SC66 showed a dose-response cleavage of 
PARP and a decrease in anti-apoptotic proteins Bcl2 and 
survivin (Figure 2D). In Huh7 cells after SC66 treatment 
the same proteins maintained the baseline levels observed 
in untreated cells (Figure 2D).
All these analyses highlight that the decrease in 
cell viability observed after SC66 treatment was due to 
apoptosis induction.
SC66 affects AKT/mTOR signaling in HCC 
cell lines
As SC66 is a novel allosteric AKT inhibitor 
which directly interacts with AKT and facilitates its 
ubiquitination and deactivation [24], we investigated 
whether the cytotoxic effects of SC66 were related to 
changes in AKT signaling. Western blot analysis was 
performed after SC66 treatment. As observed in Figure 3, 
the dose-response curve showed a slight increase in 
phospho-AKT expression levels in the presence of SC66 
at concentrations of 1 and 2 μg/ml, whereas phospho-AKT 
expression levels dramatically decreased after treatment 
with 4 μg/ml SC66 (Figure 3A). Analysis of total AKT 
protein levels revealed a decrease in protein already at a 
dose of 2 μg/ml SC66 in Hep3B cells. In Huh7 cells, we 
observed a slight effect on AKT expression levels only 
after treatment with 4 μg/ml SC66 (Figure 3).
We also examined phosphorylation levels of mTOR, 
a well-established down-stream target of activated AKT. 
SC66 treatment resulted in a significant fall in mTOR 
phosphorylation in Hep3B cells (Figure 3A). To confirm 
the modulation of mTOR signaling, we evaluated the 
phosphorylation levels of 4E-BP1 protein, a mTOR 
downstream target. Treatment with 4 μg/ml SC66 
reduced phospho-4E-BP1 (p-4E-BP1) and of total 
4E-BP1 protein levels in Hep3B cells (Figure 3A). In 
Huh7 cells, we observed a slight effect on both p-4E-BP1 
and total 4E-BP1 expression levels after treatment with 
SC66 (Figure 3).
Silencing of AKT partially overlaps the effects  
of SC66
To evaluate how dependent the effects of SC66 
were on target AKT expression, we silenced the AKT 
gene with a specific small interference RNA (siRNA). 
Although, after silencing of AKT by siRNA, AKT 
protein expression was reduced by 80% after 72 hours, 
AKT silencing reduced cell viability by almost 50% only 
after 7 days (Figure 3B). At the morphological level, no 
morphological features of apoptosis were observed in cells 
transfected with AKT siRNA (not shown). Therefore, the 
effect observed was less strong than the one observed 
using the pharmacological approach with SC66. These 
results suggest that the effects of SC66 are only partially 
AKT-dependent.
SC66 induces anoikis
The above results prompted us to investigate whether 
any additional mechanism(s) that could be responsible for 
the effects of SC66 activity on cell viability. Microscopic 
examination revealed that when exposed to increased 
concentrations of the drug the more sensitive Hep3B cells 
became rounded, slightly attached to each other, similar 
to beads on a string, and detached from the substrate, 
losing contact with extracellular matrix molecules (ECM) 
(Figure 4A). No evident effects were visible in Huh7 cells 
treated at the same drug doses and at the same treatment 
times (Figure 4A). Following these observations we 
hypothesized that in Hep3B cells SC66 might induce 
anoikis, a form of programmed cell death resulting from 
the loss of cell adhesion to the ECM [25–31]. Therefore, 
certain markers of anoikis, such as cytoskeleton and 
cell membrane-associated proteins, were analyzed. To 
observe the distribution of cytoskeleton microfilaments 
after treatment with SC66, Hep3B cells were stained with 
both phalloidin, which specifically stains actin filament, 
and with anti-vimentin antibody. As shown in Figure 4B, 
changes in distribution of actin and vimentin occurred 
after drug treatment, and in particular the latter seemed to 
slightly increase and accumulate in the perinuclear zone 
(Figure 4B). Western blot analysis also showed a reduction 
in E-cadherin expression levels and an induction of Snail, 
the negative regulator transcription factor of E-cadherin 
(CDH1) gene (Figure 4C) [32].
We also evaluated β-catenin protein levels as it is a 
component of adhesion complexes. As shown in Figure 4C 
β-catenin levels decreased after SC66 treatment.
Table 1: IC50 (µg/ml) values after treatment with SC66
HepG2 Huh7 Hep3B PLC/PRF/5 HA22T/VGH
24h 2.27 >4 0.82 2 2.35
48h 0.86 3.09 0.75 0.97 0.8
72h 0.77 2.85 0.47 0.92 0.75
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The effects of SC66 on FAK phosphorylation 
levels were also evaluated. Treatment with SC66 
clearly reduced the phosphorylated form of FAK 
(Figure 4B). In addition, cells floating after SC66 
exposure were not able to re-adhere to the plate after 
the inhibitor was removed and washed cells were plated 
again, suggesting that the death program is irreversible 
(data not shown).
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Figure 2: SC66 induces apoptosis in HCC cell lines. (A) Detection of apoptosis by TUNEL assay as described in the Materials and 
Methods section. Photomicrographs of Hep3B and Huh7 cells treated for 24 hours with increasing concentrations of SC66. (B) Cell death 
was determined by flow cytometry analysis of DNA stained with propidium iodide and evaluation of the percentage of events accumulating 
in the pre-G0-G1 position. Data are expressed as percentages of apoptotic cells and are the mean ± SD of two separate experiments. 
*p < 0.05, **p < 0.001 versus control. (C) The levels of caspase activity in the cells were measured by the Caspase-Glo® 3/7 assays after treatment 
with 0, 2, 4 μg/ml of SC66. Data are expressed as relative luminescence units (RLU) and are the means ± SD of three separate experiments, 
each of which was performed in duplicate. *p < 0.05, **p < 0.001, versus control. (D) PARP cleavage induction and levels of survivin, and Bcl2 
proteins were analyzed by Western blot. The data shown represent three independent experiments with comparable outcomes. The arrowhead 
indicates the 85 kDa form of PARP.
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SC66 induces ROS production in Hep3B cells
Many compounds may sensitize cancer cells to anoikis 
through ROS generation [33–36]. In addition, ROS have 
also been reported to be important mediators of anoikis and 
also to be related to caspase activation [34, 36]. Consequently, 
we investigated whether SC66 antitumor activities in HCC 
cells were initiated through ROS generation.
Using the cell-permeable fluorescent probe H
2
DCFDA, 
we found that SC66 treatment induced intracellular ROS 
production in Hep3B cells in a dose-dependent manner 
(Figure 5). Treatment with antioxidants, such as N-Acetyl-
cysteine (NAC), a ROS scavenger, should abrogate ROS 
effects. For this purpose cells were pretreated with 2 mM 
NAC for 2 hours before being treated with SC66. As shown 
in Figure 5 the intensity of the fluorescence probe increased 
in the presence of SC66, and decreased when cells were 
treated with SC66 in the presence of NAC.
Treatment with NAC reverts the cytotoxic 
effects of SC66 in Hep3B cells
We hypothesized that by inhibiting ROS effects 
NAC might revert the effects of SC66 on cell viability, and 
also inhibit SC66-induced anoikis. In order to validate this 
hypothesis we evaluated cell viability after SC66 treatment 
with and without NAC. The histograms in Figure 6A 
demonstrated that the presence of NAC reverted the effects 
of SC66 on cell viability at low drug doses, whereas it 
partially inhibited the effects at 4 μg/ml. At the molecular 
level, Western blot analysis also showed an almost complete 
recovery of phosphorylated and total AKT levels in Hep3B 
cells treated with SC66 in the presence of NAC (Figure 6C), 
as well as inhibition of PARP cleavage (Figure 6C).
As mentioned above, many drugs may sensitize 
cancer cells to anoikis through ROS generation. In the 
presence of NAC, a reduction in the number of rounded 
and floating Hep3B cells was observed, with cells spread 
on the plate surface even when treated with SC66, 
suggesting that NAC also abrogates the phenotypic effects 
of SC66 on cell morphology (Figure 6B).
In addition, Western blot analysis demonstrated that 
after treatment with SC66 in the presence of NAC both 
E-cadherin and FAK phosphorylation levels were almost 
restored (Figure 6D), therefore we can assume that anoikis 
was induced by SC66 via ROS production.
ROS are known to induce DNA damage, therefore 
we evaluated the expression of the phosphorylated form 
of H2AX (γ-H2AX), a well-known marker of double 
strand DNA breaks (DSBs). γH2AX was strongly induced 
Figure 3: Effects of SC66 on the phosphorylation status of critical components of the cellular signaling pathway. 
(A) Western blot analysis of phospho- and total-AKT, phospho- and total-mTOR, phospho- and total- 4E-BP1 in a dose-dependent 
treatment. β-actin served as a loading control. The data shown represent three independent experiments with comparable outcomes. 
(B) (left) Cell viability of Hep3B cells transfected with siRNA AKT and siRNA NC was assessed by MTS assay. Data are expressed as the 
percentage of control cells and are the means ± SD of three separate experiments, each of which was performed in triplicate. (right) Western 
blot of target protein in cells transfected with siRNA AKT and siRNA NC.
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after SC66 treatment and returned to the baseline levels 
of untreated cells after treatment with NAC (Figure 6C). 
These results suggested that ROS generation promotes 
DNA damage in Hep3B cells treated with SC66 and 
therefore contributes to cell death induction.
SC66 significantly potentiates the effects of 
doxorubicin and everolimus in Hep3B cells
We next examined combination of SC66 with 
conventional chemotherapeutic drugs, such as doxorubicin, 
Figure 4: SC66 induces anoikis. (A) Photomicrographs showing the morphology of Hep3B and Huh7 cells after SC66 treatment. 
(B) Immunofluorescence staining of DAPI (blue), vimentin (red) and phalloidin (green) in Hep3B cells treated with SC66 at 2 and 4 μg/ml 
for 24 hours. Morphological changes in cytoskeleton organization are visible after treatments. (C) Western blot analysis demostrating induction 
of Snail and decreases in phospho-FAK, E-cadherin and β-catenin protein levels. The data shown represent two independent experiments with 
comparable outcomes. β-actin immunolabeling was performed as a loading control.
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which is used in clinical protocols for HCC treatment, or 
with new target specific drugs, such as the mTOR inhibitor 
everolimus (also known as RAD001), currently under 
clinical trials in different cancer types, including HCC. We 
measured the cytotoxic effects after 24 hours of combination 
of SC66 with doxorubicin and with everolimus in both 
HCC cell lines using MTS assays (Figure 7). Hep3B and 
Huh7 cells were treated with SC66 at a single concentration 
(1 μg/ml) and two different concentrations of doxorubicin 
(62.5 and 125 nM) (Figure 7A), or three concentrations of 
everolimus (10-50-100 nM) (Figure 7B). In comparison 
with single treatments, combination treatments significantly 
reduced cell viability only in Hep3B cells.
SC66 displays anticancer activity in vivo
To demonstrate the effectiveness in vivo of SC66 
on HCC, a mouse xenograft tumor model of Hep3B cells 
was used. When tumors became palpable, at a size of 
about 150 mm3, mice were randomized into three groups 
of 6 animals each. The treated group received SC66 at 15 
and 25 mg/Kg twice a week via i.p. injection, while the 
untreated group received the vehicle alone. Treatment with 
25 mg/Kg SC66 significantly reduced tumor volume to 37% 
on day 17 when compared with tumors of the untreated 
group (Figure 8A). Changes in animal body weight were 
also monitored. As observed in Figure 8B, mice treated 
with 25 mg/kg SC66 did not show a significant loss of body 
weight when compared with mice treated with vehicle 
alone, suggesting a satisfactory level of drug cytotoxicity.
Western blot analysis performed on homogenates 
from tumor tissues of mice treated with SC66 showed 
lower p-AKT levels (Figure 8C) than those of untreated 
mice. Unexpectedly, we did not observe the reduction in 
total AKT levels found in in vitro studies. Nevertheless, 
immunohistochemical analysis showed an increase in the 
number of apoptotic cells (TUNEL assays), and a lower 
proliferation marker Ki-67 expression in tumor tissues 
from animals treated with SC66, than in the tissues of the 
untreated animals (Figure 8D).
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Figure 6: The antioxidant NAC reverts SC66-induced anoikis, cell growth and AKT signaling inhibition. (A) Cell 
viability was assessed by MTS assays. Hep3B cells were pre-treated with antioxidant NAC for 2 hours and then treated with SC66 at 
the indicated concentrations for 24 hours. Data are expressed as the percentage of control cells and are the means ± SD of three separate 
experiments, each of which was performed in triplicate. *p < 0.05, **p < 0.001 versus control. (B) Bright field photomicrograph of 
Hep3B cells pre-treated with NAC (2 mM) for 2 hours and then treated with different concentrations of SC66 for 24 hours. The changes 
in cell morphology after SC66 treatment were reverted in the presence of NAC. (C) The levels of AKT, mTOR, Bcl2, survivin, γ-H2AX 
proteins and PARP cleavage induction were analyzed by Western blotting. Cells were treated with different concentrations of SC66 for 24 
hours with or without NAC (2 mM). The data shown represent three independent experiments with comparable outcomes. The arrowhead 
indicates the 85 kDa form of PARP. (D) Phosphorylated levels of FAK and E-cadherin levels were determined by Western blotting after 
SC66 treatment with or without NAC (2 mM). The data shown represent two independent experiments with comparable outcomes.
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Figure 7: SC66 significantly reduced cell viability in combination with doxorubicin and everolimus in Hep3B 
cells. Cell viability was assessed by MTS assays. Hep3B cells and Huh7 cells were treated with combination of SC66 and doxorubicin 
(A) or everolimus (B) at the indicated doses for 24 hours. Data are expressed as the percentage of control cells and are the means ± SD 
of three separate experiments, each of which was performed in triplicate. *p < 0.05 versus single treatments.
Oncotarget1717www.impactjournals.com/oncotarget
DISCUSSION
HCC is the predominant form of primary liver 
cancer and the third cause of cancer-related death 
worldwide. The survival rate for most HCC patients 
is extremely low, due to the lack of appropriate and 
effective therapy, therefore developing novel therapeutic 
strategies is a high priority. Considering that the PI3K/
AKT/mTOR pathway is a key pathway in HCC, as 
its activation induces cell proliferation and increases 
survival and therapy resistance, in the present study we 
investigated the potential antitumor activity of SC66, a 
novel allosteric inhibitor of AKT activity, on HCC cell 
lines. SC66 affects AKT/mTOR signaling in HCC cells as 
shown by a decrease in AKT phosphorylation levels and 
in total protein levels. Following signaling inactivation we 
also found a reduction in the levels of mTOR and 4E-BP1 
phosphorylation, downstream targets of AKT signaling. 
Figure 8: The effect of SC66 on xenograft models of Hep3B cells. (A) Effect of SC66 on tumor growth. Once tumors were engrafted 
and palpable, mice (n = 6) were treated twice a week with SC66 at the indicated concentrations, as described in Materials and Methods. The 
curve of tumor growth was compared with that of control mice treated with vehicle alone, *p < 0.05. (B) Body weight alteration analysis. 
Mice treated with 25 mg/kg SC66 were weighed twice a week and the weight presented in the graphs. (C) Representative Western blot 
showing AKT and phospho-AKT levels of two mice treated with vehicle alone (control, C1 and C2) and two mice treated with 25 mg/kg SC66 
(T1 and T2). (D) Immunohistochemical staining was performed on formalin-fixed paraffin-embedded tumor tissues. Tissue from control 
mice and mice treated with 25 mg/kg SC66 were stained for Ki-67 proliferation index and apoptosis (TUNEL staining).
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SC66 decreased cell growth in a dose- and time-dependent 
manner in all the HCC cell lines studied. However, each 
cell line demonstrated a different sensitivity to the drug, 
with Hep3B cells being the most sensitive cell line, and 
Huh7 cells the least responsive. The reasons for the 
different behavior remain elusive and the mechanism(s) 
of resistance to SC66 has to be elucidated. One possibility 
could be related to the different characteristics of 
differentiation, biological behavior and genetic defects 
of the different cell lines reflecting the heterogeneity 
observed in primary HCC tissues.
Inhibition of cell viability in Hep3B cells was 
associated with apoptosis induction, which correlated 
with caspase-3/7 activation, PARP cleavage and down-
regulation of anti-apoptotic proteins Bcl2 and survivin.
However, the Hep3B cells did not display the 
classical morphological features of apoptotic cells. 
After treatment with SC66 in Hep3B cells, we observed 
strong changes in morphology causing a loss of cell 
contact with the extracellular matrix molecules. The cells 
became rounded, slightly attached to each other, similar 
to beads on a string, and were floating. The hypothesis 
that the cell death observed might be anoikis, a form of 
apoptosis resulting from the loss of cell adhesion to the 
extracellular matrix molecules [26–31], was confirmed 
by the following observations: first, a down-regulation 
of E-cadherin levels and an up-regulation of Snail (the 
negative regulator transcription factor of the E-cadherin 
(CDH1) gene) [32], both considered to be markers of 
anoikis [28–32]; second, changes in the distribution 
of vimentin which slightly increased and accumulated 
in the perinuclear zone; third, a redistribution of actin 
cytoskeleton as observed after staining with phalloidin; 
and finally, a clear reduction in the phosphorylated form 
of FAK, a kinase that regulates cell adhesion and acts as 
a signal transducer in response to integrins [37, 38]. It is 
worth noting that cells which became non-adherent after 
SC66 exposure were not able to re-adhere to the plate 
after the inhibitor was removed, suggesting that the death 
program was irreversible.
Many compounds may sensitize cancer cell to 
anoikis through ROS generation [33–36]. ROS have 
been reported to be important mediators of anoikis and 
are related to caspase activation [33, 36]. Recent evidence 
suggests that disruption of integrin contact with fibroblasts 
can lead to cell detachment which is preceded by a rise in 
intracellular ROS levels [31]. On the other hand, it has 
been demonstrated that detachment of endothelial cells 
resulted in a dramatic rise in ROS levels and, furthermore, 
that this rise contributed to anoikis [34]. On the basis of 
this evidence and our observations, we ascertained the 
effects of SC66 on ROS production. Measurement of ROS 
levels demonstrated a dose-dependent increase in ROS 
after treatment with SC66, suggesting that anoikis might 
be due to the presence of high levels of ROS, as confirmed 
by the reversion of SC66 effects on cell morphology, cell 
viability, E-cadherin and vimentin levels as well as on 
FAK phosphorylation observed after treatment with the 
antioxidant NAC. In cells co-treated with the antioxidant, 
an almost complete recovery of phosphorylated and total 
AKT was also observed, as well as inhibition of PARP 
cleavage. Finally, levels of γH2AX, known to be a marker 
of DNA damage, were strongly increased after SC66 
treatment and levels in treated cells returned to baseline 
after treatment with NAC.
Interestingly, SC66 significantly potentiates the 
effects of both conventional chemotherapeutic drug 
(doxorubicin) and molecularly targeted anticancer agent 
(everolimus), offering new opportunity for treatment 
of HCC.
In summary, our in vitro results demonstrated for 
the first time that SC66 affects HCC cell growth and this 
was due to the inhibition of AKT pathways and ROS 
induction, and that both of these contributed to HCC 
cell death. Furthermore, the antitumor effects of SC66 
were confirmed in vivo. In the mouse xenograft tumor 
model of Hep3B cells, SC66 treatment significantly 
reduced tumor volume to 37% on day 17 of treatment 
when compared with tumors in the untreated group. The 
inhibition of cell growth correlated with a reduction in 
phospho-AKT levels in the tumors of animals treated 
with SC66. However, unexpectedly, we did not observe 
the reduction in total AKT levels observed in vitro, and 
the reason for this result is not understood. Nevertheless, 
immunohistochemistry analysis revealed a reduction in 
cell proliferation markers and a higher degree of apoptosis 
in tumor tissues examined from xenograft mice treated 
with SC66 than in controls.
Overall, our results for the first time highlight the 
potential of the novel AKT inhibitor SC66 as a therapeutic 
drug for HCC treatment, providing the rationale for future 
experimental use in humans.
MATERIALS AND METHODS
Cell lines, cell culture and reagents
The human hepatocarcinoma cell lines HepG2, 
Huh7, PLC/PRF/5, Hep3B and HA22T/VGH used in this 
study had a low passage number and were maintained 
in RPMI medium (SIGMA, Milan, Italy), containing 
10% (v/v) Fetal Bovine Serum (FBS) (GIBCO, Life 
Technologies, Monza MB, Italy). HepG2, Huh-7 and 
HA22T/VGH cells used in this study were a gift from 
Prof. M. Levrero (Department of Internal Medicine, 
Sapienza University, Rome, Italy). Hep3B and PLC/PRF/5 
cells used in this study were a gift from Prof. O. Bussolati 
(Unit of General and Clinical Pathology, Department of 
Experimental Medicine, University of Parma, Parma, 
Italy). The HCC cell lines have different characteristics 
of differentiation, biological behavior and genetic defects 
[39]. SC66 was purchased from Cayman Chemicals (Ann 
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Arbor, MI, USA). Doxorubicin and everolimus (RAD001) 
were purchased from SIGMA.
Cell viability assays
Cells (5 x 103/well) were distributed into each well 
of 96-well microtiter plates and then incubated overnight. 
At time 0, the medium was replaced with fresh complete 
medium and different doses of SC66 were added. Cells 
were cultured for 24, 48 and 72 hours. At the end of 
treatment, MTS assays were performed using the CellTiter 
Aqueous OneSolution kit (Promega Corporation, Madison, 
WI, USA) according to the manufacturer’s instructions. 
Cell viability was expressed as a percentage of the 
absorbance measured in the control cells. Values were 
expressed as means ± SD of three separate experiments, 
each performed in triplicate. In recovery experiments, cells 
were pre-treated with the antioxidant N-Acetyl-cysteine 
(NAC) (SIGMA) for 2 hours and then the drug was added.
Caspase activity assays
Cells (2 x 104/well) were treated with 2 and 4 μg/ml 
SC66 and after 1, 3 and 6 hours the levels of caspase3/7 
activities in the cells were measured by the Caspase-Glo® 
3/7 Assay (Promega) according to the manufacturer’s 
instructions. Results were expressed as relative luminescence 
units (RLU). Values were the mean ± SD of two separate 
experiments, each performed in duplicate.
Western blot analysis
Whole cellular lysates from 0.5 x 106 cells were 
obtained using RIPA buffer (Cell Signaling Technologies 
Inc., Beverly, MA, USA) and Western blots were 
performed using the methodology for the Odyssey® 
infrared imaging system (LI-COR Biosciences, NE, 
USA). After transfer nitrocellulose membranes were 
placed in Odyssey® blocking buffer (OBB, LI-COR) 
diluted in tris-buffered saline (TBS) and incubated for 
1 hour at room temperature. Primary antibodies were 
diluted in OBB. Secondary antibodies conjugated to 
IRDye® 800CW (LI-COR) or Alexa Fluor 680 (Molecular 
Probes, Invitrogen Carlsbad, CA, USA) were diluted in 
OBB. Membranes were scanned and analyzed with an 
Odyssey IR scanner using Odyssey 3.0 imaging software. 
Antibody signals were analyzed as integrated intensities 
of regions defined around the bands of interest in either 
channel, with primary antibodies raised against survivin 
(Abcam Limited, Cambridge, UK), β-actin (SIGMA), 
phospho-AKT, AKT, phospho-mTOR, mTOR, phospho-
4E-BP1, 4E-BP1, PARP and Bcl2 (Cell Signaling 
Technologies), phospho-FAK, E-cadherin and β-catenin 
(BD Transduction Laboratories, Lexington, KY, USA), 
Snail (Santa Cruz, Dallas, Texas, USA).
Flow cytometry analysis
After 24 hours of SC66 treatment, 1 x 106 cells were 
collected and stained with propidium iodide (PI) 
(Invitrogen) and the percentage of apoptotic cells was 
determined as previously described [39].
Measurement of reactive oxygen species (ROS)
The intracellular accumulation of ROS was determined 
using the fluorescent probe 2’,7’-difluorodihydrofluorescein 
diacetate (H
2
DCFDA) (Invitrogen). Cells (2 x 105) were 
treated with various concentrations of SC66 for the indicated 
time and then incubated with the probe (1 μM) in the dark 
at 37°C, 5% CO
2
 for 15 min. Cells were observed with 
fluorescence microscopy (Leica GmbH, Germany) and 
photographed.
TUNEL assays
Cells (2 x 104/well) were cultured in 8-well 
chamber slides overnight. After treatment for 24 hours 
with various concentrations of SC66, cells were washed 
twice with PBS and fixed in 4% paraformaldehyde 
solution for 25 min at room temperature. Apoptotic cells 
were detected by terminal deoxynucleotidyl transferase-
mediated dUTP nick end-labeling (TUNEL) assay using 
the DeadEndTM Colorimetric TUNEL System Kit from 
Promega, following the manufacturer’s instructions. Cells 
were visualized with an Axioskop microscope (Zeiss, 
Oberkochen, Germany).
Colony formation assays
Cells (1.0 x 103/well) were plated in six-well plates 
in growth medium, and after overnight attachment cells 
were exposed either to SC66 or vehicle for 48 hours. The 
cells were then washed and allowed to grow for 14 days 
in drug-free conditions, after which the cell colonies were 
fixed with 70% ethanol at 4°C for 20 min and stained with 
crystal violet (0.1% in H
2
O) for 5 min. The plates were 
rinsed with water, air-dried, photographed and evaluated 
for colony estimation. Colonies containing more than 
50 cells were counted. All experiments were performed in 
duplicate and repeated twice.
Small interfering RNA (siRNA) transfection
Hep3B cells (3 x 105) were cultured in 6-well plates 
in 2 ml of RPMI medium in 10% FBS. After 24 hours the 
cells at 30–50% confluences were transfected in serum-
free medium with pre-validated human AKT siRNA 
(Qiagen, Germantown, MD, US) or control (scrambled) 
siRNA (Qiagen) at a final concentration of 50 nM, using 
RNAiMAX (Invitrogen, Carlsbad, CA) following the 
manufacturer’s instructions. 24 hours after transfection 
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cells were trypsinized, counted and plated in 96-well 
plates for MTS assay and in 3 cm diameter Petri dishes 
for protein extraction. All experiments were performed in 
triplicate and repeated twice.
Immunofluorescence staining
Cells (2 x 105/well) were cultured in 8-well chamber 
slides. After 24 hours cells were treated with SC66, after 
which they were fixed in 3.7% paraformaldehyde for 
15 minutes, and permealized using 0.25% Triton-X-100 
for 5 minutes at room temperature. Cells were then 
incubated for 1 hour with monoclonal anti-vimentin 
antibody (Santa Cruz) in 1% bovine serum albumin 
(BSA) in PBS at room temperature in a moist chamber. 
Immunofluorescence staining was obtained by incubation 
for 1 hour with secondary antibodies conjugated to Alexa 
Fluor 555 (Invitrogen). Actin staining was performed 
using phalloidin (SIGMA) and incubated with cells for 30 
min at room temperature. Cells were counterstained with 
DAPI, mounted on slides and examined with fluorescence 
microscope (Zeiss).
In vivo studies
Male nude athymic mice (Fox1 nu/nu) aged 4 
weeks were obtained from Harlan (Udine, Italy) and 
allowed to acclimatize for 1 week. Suspensions of 
10 × 106 Hep3B cells in 0.2 ml of PBS were inoculated into 
the right flank of the animal. When tumors became palpable 
(around 150 mm3), the mice were randomly divided into 
three groups of 6 animals each, with the various tumor 
volumes equally distributed among the three groups. Two 
groups of mice were treated twice a week with 15 and 25 
mg/Kg SC66 suspended in DMSO, further diluted in a 
solution of 25% ethanol and administered via i.p. injection. 
The control group received the vehicle alone. Tumor 
volumes were determined twice a week using calipers. 
Primary tumor volumes were calculated with the formula: 
v = length × (width)2/2. Mice were euthanized by cervical 
dislocation when the tumor burden exceeded 10% of animal 
body weight, or when tumor ulcerated or other conditions of 
morbidity were ascertained, in conformity with institutional 
guidelines which are in compliance with national (D.L., 116 
G.U., Suppl.40; 18 February 1992) and international laws 
and policies (ECC Council Directive 86/609, OJ L358.1, 12 
December 1987). This study was authorized by the Italian 
Ministry of Health (D.M. n. 39/2014-B).
Immunohistochemistry (IHC) analyses
Immunohistochemical studies were performed on 
formalin-fixed paraffin-embedded tumor tissues. Serial 
sections (4 μm thick) on glass slides were washed in 
xylene and hydrated in decreasing concentrations of 
alcohol. For antigen retrieval the slides were heated 
in sodium citrate solution (pH 6.0) at 96°C for 20 min. 
Endogenous peroxidase activity was quenched with 3% 
hydrogen peroxide in methanol for 30 min. Then the slides 
were treated with 1% BSA for 30 min and incubated for 
1 hour at room temperature in the presence of 0.1% BSA 
with a monoclonal rabbit antibody for nuclear antigen, 
Ki-67 (1:100) (Biocare Medical, CRM325). At the end, 
the sections were treated for 30 min with secondary 
biotinylated immunoglobulin anti-rabbit antibody 
(DAKO, LSAB Kit, K0690, Denmark). The sections 
were then incubated with a streptavidin-horseradish 
peroxidase conjugate for 1 hour, followed by chromogen 
3-3′ diaminobenzidine tetrahydrochloride for 1 min, and 
counterstained with Mayer’s hematoxylin. The specific 
primary antibody was replaced with PBS in tissue sections 
used as negative controls. All immunostained sections were 
analyzed at a × 400 magnification (five fields). Images of 
stained slides were captured using Leica DMR microscope 
equipped with a Leica DFC 320 digital camera.
Apoptotic cells were detected by TUNEL assay 
using the DeadEndTM Colorimetric TUNEL System Kit 
from Promega, following the manufacturer’s instructions. 
Cells were visualized with an Axioskop microscope 
(Zeiss).
Statistical analysis
Statistical analysis was performed using Student’s 
two-tailed t test. Statistical significance was p < 0.05.
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